Second primary malignancies in patients with neuroendocrine tumors

Reina, J. J.; Serrano, Raquel; Codes, M.; Jiménez, E.; Bolaños, M.; González, Encarnación; Sevilla, Isabel

doi:10.1007/s12094-014-1174-x

Cited by 5 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of reports have also demonstrated increased risk of additional malignancies occurring in the NET patient set [8,9,10,11,12,13,14], a factor which may add to the already challenging management of individuals with NET if coexistent. With the aforementioned relatively prolonged natural history of this tumour type, this presents a pertinent clinical consideration.…”

Section: Introductionmentioning

confidence: 99%

Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours

Clift

Drymousis²,

Al‐Nahhas³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

Background: An association between neuroendocrine tumours (NET) and increased risk of developing second primary malignancies (SPM) has been recognised. Methods: This was a retrospective review of our institutional prospectively maintained database of NET patients. We identified patients who had been diagnosed with both neuroendocrine and any additional malignancies via examination of patient notes. Results: Clinical data for 169 patients were analysed. After exclusion of patients known to have hereditary tumour predisposition syndromes, 29 SPM were identified in 26 patients (15.38%), the commonest being colorectal (n = 6), breast and renal carcinomas (both n = 5). SPM were classified as previous, synchronous or subsequent relative to NET diagnosis. Rates of SPM in pancreatic and small-bowel NET patients were comparable (15.7 vs. 19.6%, p = 0.78). A person-year methodology was used to compare observed numbers of SPM against expected values generated from age- and sex-specific incidence tables, with standardised incidence ratios (SIR) and 95% confidence intervals (CI) calculated. SPM incidence was significantly elevated in the synchronous subset (SIR 2.732, CI 1.177-5.382) whilst significantly fewer NET patients had a cancer history compared to the general population (SIR 0.4, CI 0.241-0.624). No overall differences were evident between observed and expected incidences of subsequent SPM (SIR 0.36, CI 0.044-1.051). The incidence of synchronous colorectal cancers was markedly elevated (SIR 13.079, CI 4.238-30.474). Conclusions: Our data support the use of colonoscopy in the diagnostic work-up of NET patients in anticipation of a colorectal SPM. The mechanistic underpinnings of this clinical phenomenon require further genetic investigation, and consideration of this knowledge in patient management pathways is warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours

Clift

Drymousis²,

Al‐Nahhas³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…In this single-institution retrospective review, the incidence of additional malignancies in patients with NETs was 11.4% [2]. Although few similar studies exist, these studies also reported similar results [16,17]. However, in these studies, very few or no reports of synchronous or metachronous tumors with Neuroendocrine tumors of the bladder were reported.…”

Section: Discussionmentioning

confidence: 55%

“…Three of these case reports involved multiple primary tumors with SCNEC of bladder: one with squamous cell carcinoma of the lung and esophagus [9], one with prostatic ductal adenocarcinoma, and penile squamous cell carcinoma [8], and one with Chronic lymphocytic leukemia [18]. Two of these cases were multiple primary tumors with non-subtype specified neuroendocrine tumors [2,17].…”

Section: Discussionmentioning

confidence: 99%

Small cell neuroendocrine carcinoma of the bladder with synchronous Warthin’s tumor of the parotid gland: A rare case and overview of the literature

Aytekin

Araz

2022

Oncol Clin Pract

View full text Add to dashboard Cite

Introduction. Neuroendocrine tumors (NETs) develop from the epithelium rich in enterochromaffin cells. NETs most commonly originate from the gastrointestinal and respiratory tract. NETs rarely occur in the urinary bladder.Synchronous tumor is defined as having two different tumors growing at the same time in an organ. NETs are frequently associated with synchronous or metachronous second-primary malignancies. In this paper, we describe a synchronous tumor: a small cell neuroendocrine carcinoma (SCNEC) of the bladder and a Warthin's tumor (WT) of the parotid gland, both of which are highly rare in the literature.Case report. A 79-year-old male patient was admitted to the hospital with gross hematuria and nodular mass involving the wall of the urinary bladder. The bladder neck resection and transurethral bladder resection (TURB) were performed. The tumor consisted of small, uniform, round, and spindled-shaped cells with chromatin dark nuclei and numerous mitotic figures. The cells were immunoreactive for CD56, synaptophysin (diffuse), and keratin (focal). The diagnosis of SCNEC with focal urothelial carcinoma in situ component was established. PET-CT was performed for staging purposes, and it showed a residual/recurrent tumor behind the lumen of the bladder floor and two nodular lesions with metabolic activity in the left parotid. After the biopsy of the parotid gland, it was diagnosed as WT. No metastasis of SCNEC was found at the time of diagnosis, and the patient received four cycles of induction chemotherapy (Etoposide combined with carboplatin chemotherapy) followed by chemoradiotherapy. Conclusion.In this case report, an extremely rare case of primary SCNEC of the bladder with synchronous of the parotid gland is presented, along with a discussion on the clinical presentation, immunohistochemical and cytomorphological characteristics, management, biological behavior, and prognosis.

show abstract

“…Patients with a GEP‐NET were diagnosed with an SPM more frequently. This is a slighter higher proportion than described in literature, ranging from 9.8% to 18.9% [25–27]. This can be explained by the fact that we included all patients with an SPM, whilst other studies excluded patients with any genetic predisposition syndrome.…”

Section: Discussionmentioning

confidence: 78%

Evaluation of quality of clinical management of neuroendocrine tumors

et al. 2022

View full text Add to dashboard Cite

Background: Neuroendocrine tumors (NETs) are a group of biologically and clinically heterogeneous neoplasms predominantly found in the gastrointestinal and bronchopulmonary tractus. Despite a rising incidence, implementation of evidence-based standardized care for this heterogenous group remains challenging. The European Neuroendocrine Tumor Society regularly reviews guidelines regarding diagnostic and treatment strategies for NETs. The aim of this study is to shed light on the care of patients with a NET in Belgian Limburg, to provide data as a basis for future studies and to check whether data and results are according to consensus guidelines and outcomes described in literature. Methods: Our study concerned a detailed observational data collection of two large Belgian hospitals (Jessa Hospital Hasselt and Hospital Oost-Limburg Genk) with special interest in patient profile, quality of pathology reports, use of diagnostic imaging, and overall survival. Data on 188 patients were assembled between January 2010 and December 2014 with follow-up until June 2016 (median follow-up: 33.6 months).Results: Fifty percent of patients were male. NETs were located mainly in the digestive tract (63.8%) and lung (20.2%). Appendiceal NETs were diagnosed at a significantly younger age than other tumors (41.3 vs. 64.0 years). Overall, a mean pathology report quality score of 3.0/5 was observed with the highest scores for small bowel NETs. Diagnostic and nuclear imaging was performed in 74.5% and 29.8% of cases, respectively. Seventy-four percent of the population survived until the end of the observation period with highest survival rates for appendiceal and small bowel NETs.

show abstract

Second primary malignancies in patients with neuroendocrine tumors

Cited by 5 publications

References 18 publications

Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours

Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours

Small cell neuroendocrine carcinoma of the bladder with synchronous Warthin’s tumor of the parotid gland: A rare case and overview of the literature

Evaluation of quality of clinical management of neuroendocrine tumors

Contact Info

Product

Resources

About